Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;49(2):632-651.
doi: 10.1007/s00259-021-05603-w. Epub 2021 Dec 9.

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Eric Guedj  1   2 , Andrea Varrone  3 , Ronald Boellaard  4   5 , Nathalie L Albert  6 , Henryk Barthel  7 , Bart van Berckel  4 , Matthias Brendel  6   8 , Diego Cecchin  9 , Ozgul Ekmekcioglu  10 , Valentina Garibotto  11   12 , Adriaan A Lammertsma  4   5 , Ian Law  13 , Iván Peñuelas  14 , Franck Semah  15 , Tatjana Traub-Weidinger  16 , Elsmarieke van de Giessen  4   17 , Donatienne Van Weehaeghe  18 , Silvia Morbelli  19   20
Affiliations

EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

Eric Guedj et al. Eur J Nucl Med Mol Imaging. 2022 Jan.

Erratum in

  • Correction to: EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3.
    Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, Morbelli S. Guedj E, et al. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2100-2101. doi: 10.1007/s00259-022-05755-3. Eur J Nucl Med Mol Imaging. 2022. PMID: 35254483 Free PMC article. No abstract available.

Abstract

The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.

Keywords: Dementia; Encephalitis; Epilepsy; Glioma; Glucose; Lymphoma; Metabolism; Movement disorders; Oncology; PET; Psychiatry.

PubMed Disclaimer

Conflict of interest statement

BvB received research support from ZON-MW, AVID radiopharmaceuticals, CTMM, IXICO, Springer and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria.

EG has received consultant and speaker honoraria from GE Healthcare and CIS Bio International; and consultant honoraria from Advanced Accelerator Applications.

HB has received speaker honoraria from AAA/Novartis.

IL has received speaker honoraria from Siemens Healthcare.

MB has received speaker honoraria from GE healthcare, Roche, and LMI and is an advisor of LMI.

SM has received speaker honoraria from GE Healthcare and Advanced Accelerator Applications.

VG has received research/teaching funding through her institution from Siemens Healthineers, GE Healthcare, Roche, Merck, Cerveau Technologies and Life Molecular Imaging.

AV is at present employed at H. Lundbeck A/S.

The other authors declare that they have no conflict of interest.

References

    1. Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393–395. doi: 10.1038/nn.4492. - DOI - PMC - PubMed
    1. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction-the disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019;15:158–167. doi: 10.1016/j.jalz.2018.07.222. - DOI - PMC - PubMed
    1. Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13:eabe5640. 10.1126/scitranslmed.abe5640. - PubMed
    1. Verger A, Lagarde S, Maillard L, Bartolomei F, Guedj E. Brain molecular imaging in pharmacoresistant focal epilepsy: current practice and perspectives. Rev Neurol. 2018;174:16–27. doi: 10.1016/j.neurol.2017.05.001. - DOI - PubMed
    1. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–2110. doi: 10.1007/s00259-009-1264-0. - DOI - PubMed

Substances

LinkOut - more resources